Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease

Summary

The primary objective of the study is to evaluate the safety and tolerability of a range of single BIIB054 doses, administered as a single intravenous (IV) infusion, in healthy participants and participants with early Parkinson's disease (PD). Secondary objectives of the study are to assess the serum pharmacokinetics (PK) profile of BIIB054 after single-dose administration and to evaluate the immunogenicity of BIIB054 after single-dose administration.

Timeline

Start

2015-07-01

Primary completion

2017-11-20

Completion

2017-11-20

Drugs

Indications